Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2

NCT04335032 is registered in ClinicalTrials.gov with S.L.A. Pharma AG as lead sponsor.

NCT NCT04335032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2
Lead sponsor
S.L.A. Pharma AG
Phase
Phase 3
Overall status
Unknown status
Start date
January 8, 2021
Completion date
December 1, 2021
Enrollment
284 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2